YBRAIN

Ybrain operates at the intersection of neurotechnology, medical devices, and digital mental health. Its product set combines MindScan, a 19-channel dry-electrode EEG system for monitoring and quantitative analysis, with MindStim, a home-use transcranial electrical stimulation device described for major depressive disorder. The company also lists HD-tDCS, a migraine-focused nerve-stimulation device, and software for clinical scales and mental-health monitoring. This mix distinguishes its approach from a single-device or assessment-only offering: it seeks to link brain-signal measurement, clinical evaluation, and intervention. The available company information does not identify named direct competitors, so a reliable company-by-company comparison is not possible. Competitive pressure is likely to come broadly from firms developing EEG diagnostics, non-invasive neuromodulation devices, and digital therapeutics. Ybrain’s stated differentiators are its combination of hardware and software, its focus on neuropsychiatric applications, and its clinical and distribution partnerships in South Korea. Those advantages will depend on clinical validation, regulatory progress, and the ability to establish routine use in care settings; product descriptions alone do not establish comparative efficacy or market leadership.

Ybrain’s funding history indicates a progression from early-stage financing to later private-equity funding, although round details are incomplete and reported labels do not align perfectly. The recorded history begins with a $645,050 Seed round in February 2013, followed by a $3.5 million Series A in August 2014 and a Series B in August 2015 with no confirmed amount in the round record. Additional entries include an undated Series C and strategic investment, a 2020 Venture Round, and a $9.22 million Private Equity round on Feb 23, 2022. The company’s reported structured funding total is $13.37 million. Product development has broadened from non-invasive stimulation into EEG diagnostics and tools for clinical assessment and mental-health monitoring. The July 2026 Korea Pharma agreement marks a commercial distribution step for MindScan and MindStim across Korean clinics, while the 2024 Friend & Companion partnership also targeted diagnostic-market expansion. The key inflection point is therefore a shift toward commercialization through partnerships, alongside an established but incompletely documented financing and product-development history.